GrOwnValve
Deine Herzklappe. Körpereigen. Lebenslang.
Scroll for more

Overview

At GrOwnValve we are saving lives
through innovation

Every year 1.35m babies wordwide are born with a congenital heart defect. 400,000 of them suffer from a heart valve defect but currently there is no durable valve replacement available on the market. We are planning to meet that clinical demand with a completely new prosthetic valve for adults and children which is implanted using a low-risk transcatheter technique. Our valve is made from patient-donated (endogenous) tissue, giving it a life-long durability: a once-in-a-lifetime solution that is affordable for both patients and healthcare providers worldwide.

Medical Need

Our innovation

Status

GrOwnValve is a clinical stage medical device company, developing a unique heart valve prosthesis system. Our AdultValve and ChildValve are made from the patients‘ own tissue and, including a bioresorbable anchoring device, will be available as part of a procedure pack that enables a safe, affordable and easy-to-use minimally invasive heart valve replacement.

Our goal

Our main goal is to offer a lifelong cure to patients worldwide who have heart valve defects. Our innovation eliminates the need for patients to undergo repetative heart valve replacement surgery and to accept medication throughout their whole lives.


Our team

Boris Schmitt

CEO

Boris Warnack

CTO

Jordi Modolell

Team Lead R&D

Alexander Breitenstein

Team Lead R&D

Marvin Steitz

Team Lead R&D

Carlo Wentzel

R&D Engineer

Mahamuda Khan

R&D Scientist

Aileen Grabowski

Quality Management & Regulatory Affairs (QMB)

Johanna Ticar

Project Management

Florence Kosche

R&D Engineer

Axel Mewes

Human Resources

News

We are glad to announce that we got funded by the DZHK for conducting our first clinical trial in adult patients starting in 2022.

The GrOwnValve is now officially aligning their 3D-Printing Processes to ISO/ASTM Standards with the help of the Qualified AM Program.

Breaking News: Our Groundbreaking Heart Valve Project Featured in Major Newspaper!

We are very happy to be nominated #ScienceBreakthrough of the year by the Falling Walls Foundation award!

In 2019 Spark helped kick-start the bioresorbable stent solution to make the GrOwnValve innovation a possible treatment for small (growing) patients.

In july 2018 the GrOwnValve Project Team won the BPW Canvas business plan price by the IBB Berlin.

We are very proud to have been able to be part of the research consortium that was able to reach a Sciencemag publication.

In Autumn of 2017 the GrOwnValve Project was rewarded the EXIST translational grant to bring the innovative technology into preclinical testing.

Our co-founder Jasper Emeis was interviewed about the win of the EIC by the Healthcapital online-magazin.

GrOwnValve wins the INAM Innovation Challenge 2021.

From August 2021 the EXIST II funding programme supported GrOwnValve for one year to establish Quality and Risk Management.

In November 2021, our project „Kleine Patienten – großer Bedarf“, administered by VDI, received funding by the German Federal Ministery of Education and Research.

Since April 2022, the EIC Accelerator Programme has helped with the transition of our products from research objects to their clinical application.

We are proud and happy to announce that our first clinical trial in (young) adult patients, starting in 2023, has received funding by the DZHK.

German nationwide broadcaster ZDF published a documentary on the topic of cardiac health, featuring GrOwnValve as an example of cutting edge RnD (from 37:00 onwards).

Our CEO, Dr. Boris Schmitt showcased a pioneering expandable heart valve for children at Charité BIH Innovation, emphasizing the transformative impact of research on health and society.

Dr. Boris Schmitt presents first Grownvalve clinical experiences at CSI Frankfurt—ushering transformative valve disease solutions.

On 19th June 2025, Deutsches Herzzentrum der Charité (DHZC) Berlin published an official press release telling the world about the first successful implementation of our unique heart valve prothesis from autologous tissue.

Other Projects

StealthStent

As part of our EU-funded project, we are developing a fully bioresorbable next-generation stent that:

  • provides stable mechanical support during the healing process;
  • dissolves completely within six months, thereby allowing the vessel to grow;
  • is coated with a zwitterionic polymer to prevent a foreign body reaction.

More info

ValveGuard

In this project, funded by Investitionsbank Berlin, a test bed is being developed that simulates infectious endocarditis under nearly physiological conditions.

  • Simulation of infectious endocarditis under realistic conditions.
  • Development of an innovative test bench for prosthetic heart valves.
  • Study of the development of bacterial colonization and infections.
  • Supporting the development of safer heart valve implants.

The consortium comprising GrOwnValve, MoKi Analytics, Charité – CMS, and Charité – LfB is working together toward the goal of developing a test bed that will enable research into the development of infectious endocarditis in prosthetic heart valves.

Contact us

Contact us
I agree to the Privacy Policy